Celgene preclinical data

CELG (Warren, N.J.) reported its development of a new series of compounds based on thalidomide.

As described at the meeting of the American Chemical Society in Chicago, the compounds are orally available in rodents, and appear less toxic than the parent molecule. The compounds showed initial evidence of effectiveness in a mouse model of toxic shock, and increased immunologic activity in assays using human blood cells to test for anti-inflammatory activity. ...